Matthew Wikler - Jun 19, 2021 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Director
Signature
/s/ Keith A. Kucinski, attorney-in fact for Matthew Wikler
Stock symbol
MTNB
Transactions as of
Jun 19, 2021
Transactions value $
$0
Form type
4
Date filed
6/24/2021, 05:42 PM
Next filing
Jul 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MTNB Common Stock, par value $0.0001 per share Other $0 +2.4K +0.95% $0.00 254K Jun 19, 2021 Direct F1
transaction MTNB Common Stock, par value $0.0001 per share Conversion of derivative security $0 +12K +4.72% $0.00 266K Jun 19, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Series B Preferred Stock Conversion of derivative security $0 -6 -100% $0.00* 0 Jun 19, 2021 Common Stock 12K $0.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.
F2 On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.